A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI)
Phase 1
Recruiting
- Conditions
- Premature Ovarian InsufficiencyDiminished Ovarian Reserve
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Vitti Labs, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT06072794
- Locations
- 🇺🇸
Optimal Health Associates, Oklahoma City, Oklahoma, United States
Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19
Phase 2
Recruiting
- Conditions
- Pulmonary FibrosisCOVID-19 Respiratory Infection
- Interventions
- Drug: VL-PX10 and VL-P22 plus standard careDrug: Placebo
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Vitti Labs, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05387239
- Locations
- 🇺🇸
Kit Bartalos, Liberty, Missouri, United States
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)
Phase 1
Recruiting
- Conditions
- COVID-19 Acute Respiratory Distress SyndromeRespiratory Distress Syndrome
- Interventions
- Drug: PlaceboDrug: EV-Pureâ„¢ and WJ-Pureâ„¢
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Vitti Labs, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05387278
- Locations
- 🇺🇸
Kit Bartalos, Liberty, Missouri, United States
© Copyright 2025. All Rights Reserved by MedPath